2033-44-5Relevant articles and documents
Halogenations of substituted 2-alkylquinoline with iodine and halide exchange with AgF2
Pang, Xiaobo,Xiang, Likui,Ma, Jianxin,Yang, Xiaodong,Yan, Rulong
, p. 111713 - 111717 (2016)
Halogenations of substituted 2-alkylquinoline with iodine and halide exchange with AgF2 have been developed. These processes provide facile strategies to construct C-I/F bonds, and expand the methods of fluorination of 2-alkylquinolines. These transformations exhibit good tolerance of functional groups and generate the desired products in moderate to good yields.
Electrochemical sulfenylation of indoles with disulfides mediated by potassium iodide
Chen, Chen,Niu, Pengfei,Shen, Zhenlu,Li, Meichao
, p. G67 - G74 (2018/05/22)
A novel electrochemical system for sulfenylation of indoles with disulfides to generate 3-sulfenylindoles via C-S bond formation mediated by potassium iodide at a low potential was developed. Iodine was electrogenerated from iodide ions at a graphite anode and showed a high catalytic activity for the electrochemical sulfenylation reactions. A variety of aromatic, heteroaromatic and aliphatic disulfides could react with 2-methlyindole to synthesize the corresponding 3-sulfenylindoles in good to excellent yields. In addition, protected and unprotected indoles with various groups, especially electron-donating groups, also performed well in the sulfenylation reactions. The transformation, which proceeded through the redox of iodine and the generation of intermediate 3-iodoindole, provided an efficient and environmentally benign protocol for the synthesis of 3-sulfenylindoles under mild conditions.
POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
-
Paragraph 00455, (2015/05/05)
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.